IO Biotech, Inc. (IOBT) 10-Year Financial Performance & Capital Metrics

IOBT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutIO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Show more

Revenue $0
EBITDA -$94M -4.0%
Net Income -$95M -10.9%
EPS (Diluted) -1.45 +26.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -106% -67.5%
ROIC -
Debt/Equity 0.04 +117.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 51.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM2.2%

EPS CAGR

10Y-

5Y-

3Y-

TTM1.46%

ROCE

10Y Avg-392.54%

5Y Avg-392.54%

3Y Avg-70.19%

Latest-103.9%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	540K	756K	849K
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	-540K	-756K	-849K
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-0.4%	-0.12%
Operating Expenses+	9.91M	10.14M	41.23M	70.88M	90.69M	94.33M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	1.98M	1.68M	11.08M	23.9M	22.86M	22.84M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	7.94M	8.46M	30.15M	46.99M	67.83M	71.48M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-9.91M	-10.14M	-41.23M	-71.42M	-91.44M	-95.18M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-0.02%	-3.06%	-0.73%	-0.28%	-0.04%
EBITDA+	0	-12.02M	-41.23M	-70.88M	-90.69M	-94.33M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-	-2.43%	-0.72%	-0.28%	-0.04%
D&A (Non-Cash Add-back)	9.91M	0	2K	540K	756K	849K
EBIT	-10.74M	-12.02M	-67.45M	-69.88M	-85.23M	-94.05M
Net Interest Income+	-5.99K	-25.97K	-360.64K	1.11M	5.88M	4.72M
Interest Income	6	26	361	1.41M	5.88M	4.72M
Interest Expense	6K	26K	361K	302K	0	0
Other Income/Expense	-830K	-1.9M	-26.58M	1.24M	6.21M	1.13M
Pretax Income+	-10.74M	-12.04M	-67.81M	-70.19M	-85.23M	-94.05M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	68K	1.27M	852K	1.44M
Effective Tax Rate %	1%	1%	1%	1.02%	1.01%	1.02%
Net Income+	-10.75M	-12.04M	-67.88M	-71.46M	-86.08M	-95.49M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-0.12%	-4.64%	-0.05%	-0.2%	-0.11%
Net Income (Continuing)	-10.74M	-12.04M	-67.88M	-71.46M	-86.08M	-95.49M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-60.66	-1.05	-2.36	-2.48	-1.98	-1.45
EPS Growth %	-	0.98%	-1.25%	-0.05%	0.2%	0.27%
EPS (Basic)	-60.73	-1.05	-2.36	-2.48	-1.98	-1.45
Diluted Shares Outstanding	177.2K	11.55M	28.82M	28.82M	43.54M	65.88M
Basic Shares Outstanding	177K	11.55M	28.82M	28.82M	43.54M	65.88M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.4M	5.63M	221.74M	148.22M	147.25M	64.95M
Cash & Short-Term Investments	7.85M	3.4M	211.53M	142.59M	143.19M	60.03M
Cash Only	7.85M	3.4M	211.53M	142.59M	143.19M	60.03M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	1.23M	1.5M	2.09M	1.53M	1.13M	1.13M
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	103K	371K	149K	685K	754K	803K
Total Non-Current Assets+	20K	18K	550K	3.59M	3.46M	2.75M
Property, Plant & Equipment	0	0	155K	3.23M	3.11M	2.36M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	268K	268K	0	268K
Other Non-Current Assets	20K	18K	127K	84K	357K	117K
Total Assets+	9.42M	5.65M	222.29M	151.81M	150.72M	67.7M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	-0.4%	38.32%	-0.32%	-0.01%	-0.55%
Total Current Liabilities+	10.84M	3.05M	10.3M	10.68M	15.72M	19.49M
Accounts Payable	997K	522K	3.93M	4M	3.88M	4.66M
Days Payables Outstanding	-	-	-	2.71K	1.87K	2K
Short-Term Debt	8.66M	0	0	515K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	931K	1.74M	461K	4.29M	5.03M	500K
Current Ratio	0.87x	1.85x	21.52x	13.88x	9.37x	3.33x
Quick Ratio	0.87x	1.85x	21.52x	13.88x	9.37x	3.33x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	52K	0	59K	2.27M	1.84M	1.2M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	2.27M	1.84M	1.2M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	52K	0	59K	0	0	0
Total Liabilities	10.89M	3.05M	10.36M	12.95M	17.56M	20.68M
Total Debt+	8.66M	0	0	2.79M	2.49M	1.92M
Net Debt	817K	-3.4M	-211.53M	-139.8M	-140.7M	-58.12M
Debt / Equity	-	-	-	0.02x	0.02x	0.04x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-1652.17x	-390.19x	-114.22x	-236.50x	-	-
Total Equity+	-1.47M	2.6M	211.92M	138.85M	133.16M	47.02M
Equity Growth %	-	2.77%	80.42%	-0.34%	-0.04%	-0.65%
Book Value per Share	-8.30	0.23	7.35	4.82	3.06	0.71
Total Shareholders' Equity	-1.47M	2.6M	211.92M	138.85M	133.16M	47.02M
Common Stock	28K	8K	29K	29K	66K	66K
Retained Earnings	-26.36M	-38.4M	-106.28M	-177.74M	-263.82M	-359.31M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	1.3M	1.96M	-1.49M	-10.14M	-9.67M	-6.85M
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.89M	-9.96M	-40.65M	-59.73M	-71.74M	-82.35M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.12%	-3.08%	-0.47%	-0.2%	-0.15%
Net Income	-10.74M	-12.04M	-67.88M	-71.46M	-86.08M	-95.49M
Depreciation & Amortization	0	0	2K	540K	756K	849K
Stock-Based Compensation	131K	64K	1.79M	7.04M	8.06M	6.53M
Deferred Taxes	0	0	-2K	87K	0	0
Other Non-Cash Items	828K	1.87M	26.22M	-130K	-331K	3.59M
Working Capital Changes	893K	148K	-776K	4.19M	5.86M	2.18M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	103K	-475K	3.41M	77K	-126K	782K
Cash from Investing+	0	0	-153K	-690K	-323K	-44K
Capital Expenditures	0	0	-153K	-690K	-323K	-44K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	9.01M	5.1M	252.95M	0	71.86M	0
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	-14K	-12.11M	0	-3.2M	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-8.89M	-9.96M	-40.8M	-60.42M	-72.06M	-82.39M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.12%	-3.1%	-0.48%	-0.19%	-0.14%
FCF per Share	-50.17	-0.86	-1.42	-2.10	-1.66	-1.25
FCF Conversion (FCF/Net Income)	0.83x	0.83x	0.60x	0.84x	0.83x	0.86x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-2127.56%	-63.28%	-40.74%	-63.29%	-106%
Return on Invested Capital (ROIC)	-	-	-7869.08%	-	-	-
Debt / Equity	-	-	-	0.02x	0.02x	0.04x
Interest Coverage	-1652.17x	-390.19x	-114.22x	-236.50x	-	-
FCF Conversion	0.83x	0.83x	0.60x	0.84x	0.83x	0.86x

Frequently Asked Questions

Growth & Financials

IO Biotech, Inc. (IOBT) grew revenue by 0.0% over the past year. Growth has been modest.

IO Biotech, Inc. (IOBT) reported a net loss of $88.3M for fiscal year 2024.

Dividend & Returns

IO Biotech, Inc. (IOBT) has a return on equity (ROE) of -106.0%. Negative ROE indicates the company is unprofitable.

IO Biotech, Inc. (IOBT) had negative free cash flow of $81.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener